No­var­tis of­floads five eye drugs in deal worth up to $175M

Eye care phar­ma com­pa­ny Har­row said this morn­ing that it’s ac­quir­ing the US rights to five dif­fer­ent drugs from the Swiss phar­ma No­var­tis for $130 mil­lion up­front, with $45 mil­lion more if one of the drugs lands on the mar­ket.

If the deal goes through, Har­row will hold ex­clu­sive use in the US for the four eye drop prod­ucts and one in­jectable drug.

The ad­di­tion­al $45 mil­lion will come if the steroid in­jec­tion Tries­ence hits the mar­ket, which is ex­pect­ed in the sec­ond half of next year, Har­row said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER